Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / NTLA
Stock rating · in Vitro & in Vivo Diagnostic Substances
Intellia Therapeutics, Inc (NTLA) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Intellia Therapeutics, Inc 61 out of 100 (Promising). Its highest factor score is earnings track record at 85, and its lowest is business quality at 24.
MELANY ratingRated 2026-10-06NTLA · composite score
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company developing CRISPR/Cas9-based therapeutics. CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) is a technology for precisely altering specific genomic DNA sequences, and Intellia applies it to treat genetically defined diseases.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why NTLA scores 61/100
NTLA's 8 factor scores run from 24 to 85, and 4 of them sit above its composite of 61. Here is how NTLA breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +10%
- Earnings in 30 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 87% upside
- Institutional net buying +28.3%
Near-term events that could move the stock.
- Earnings in 30 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How NTLA compares
As of October 7, 2026, Intellia Therapeutics, Inc ranks 14th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for NTLA
- Operating margin -1472%, cash-burn business, dependent on capital markets
- Negative free cash flow, company consuming cash, not generating it
- Short interest 42% of float, high volatility risk on news
- High beta 1.8, amplifies market drawdowns 1.8x+ in selloffs
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Intellia Therapeutics, Inc sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds NTLA's momentum and catalyst factors above.
NTLA trade plan (Pro)
MELANY has a full position plan for Intellia Therapeutics, Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates NTLA
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Intellia Therapeutics, Inc's 61/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about NTLA
Is Intellia Therapeutics, Inc (NTLA) a buy?
As of 2026-10-06, MELANY rated Intellia Therapeutics, Inc Promising with a composite score of 61/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Intellia Therapeutics, Inc's MELANY score?
Intellia Therapeutics, Inc (NTLA) has a MELANY composite score of 61/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the NTLA stock rating calculated?
MELANY scores NTLA from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Intellia Therapeutics, Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Intellia Therapeutics, Inc (NTLA) Promising with a composite of 61/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the NTLA stock price forecast?
MELANY does not publish price targets or forecasts for NTLA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 61/100 across eight factors for Intellia Therapeutics, Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is NTLA stock overvalued or undervalued?
MELANY's valuation factor currently reads 66/100 for Intellia Therapeutics, Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives NTLA's read.
What price should I buy NTLA at?
Rather than chasing the current price, MELANY computes a smart entry zone for NTLA: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying NTLA stock?
The top risks MELANY currently flags for Intellia Therapeutics, Inc: Operating margin -1472%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 42% of float, high volatility risk on news; High beta 1.8, amplifies market drawdowns 1.8x+ in selloffs; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Intellia Therapeutics, Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 24/100 for Intellia Therapeutics, Inc, and earnings track record, at 85/100. The 61/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will NTLA stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 46/100 for NTLA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this NTLA rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores NTLA continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, NTLA included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.